bluebird bio Reports Fiscal Third Quarter 2014 Financial Results
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended September 30, 2014.
"The third quarter of 2014 was another productive quarter for bluebird bio," said Nick Leschly, chief bluebird. "We continue to make steady progress across all our programs and we were excited to announce the treatment of our first subject with sickle cell disease using LentiGlobin BB305.
Help employers find you! Check out all the jobs and post your resume.
"The third quarter of 2014 was another productive quarter for bluebird bio," said Nick Leschly, chief bluebird. "We continue to make steady progress across all our programs and we were excited to announce the treatment of our first subject with sickle cell disease using LentiGlobin BB305.
Help employers find you! Check out all the jobs and post your resume.